CAS 1192189-69-7

3-(4-(Aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate

CAS : 1192189-69-7

Formule : C₂₃H₂₉N₇O₃

Degré de pureté : 99%

Couleur et forme : Solid

Masse moléculaire : 451.5215

Ref: IN-DA008TMD

LX7101

CAS : 1192189-69-7

LX7101

Degré de pureté : ≥98%

Masse moléculaire : 451.52g/mol

Ref: 54-BUP21996

LX7101 (3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate

CAS : 1192189-69-7

Formule : C₂₃H₂₉N₇O₃·HCl

Masse moléculaire : 451.53 36.46

Ref: 4Z-L-116001

LX7101

CAS : 1192189-69-7

LX7101 is a potent, selective, and orally bioavailable tyrosine kinase inhibitor. It inhibits the proliferation of endothelial cells (ECs) in vitro and the growth of EC-derived tumors in vivo. In both cell culture and animal models, LX7101 potently inhibits phosphodiesterase type-5 (PDE5), which is an enzyme that catalyzes the hydrolysis of cyclic guanosine monophosphate (cGMP). Inhibition of PDE5 leads to increased cGMP levels and has been shown to have therapeutic potential for the treatment of erectile dysfunction. LX7101 also blocks tyrosine kinases, which are enzymes that transmit signals from outside the cell to inside the cell. It has been shown to inhibit nerve injury in rats with peripheral nerve injury. The safety profile of LX7101 has been evaluated by toxicological studies in Sprague-Dawley rats and by clinical development in patients with cancer or cavernosal

Formule : C₂₃H₂₉N₇O₃

Degré de pureté : Min. 95%

Masse moléculaire : 451.52 g/mol

Ref: 3D-SXB18969

LX7101

CAS : 1192189-69-7

LX7101 is an effective inhibitor of LIMK and ROCK2 (IC50: 24, 1.6, and 10 nM for LIMK1, LIMK2, and ROCK2, respectively). It also inhibits PKA (IC50 <1 nM).

Formule : C₂₃H₂₉N₇O₃

Degré de pureté : 99.08%

Couleur et forme : Solid

Masse moléculaire : 451.52

Ref: TM-T15798